AI-generated from publicly available materials.Genialis and Inventia Life Sciences have formed a partnership aimed at enhancing the testing of pancreatic cancer treatments by aligning patient biology with advanced 3D cancer models.
The collaboration will leverage Genialis’ AI-driven patient insights alongside Inventia’s RASTRUM 3D cell model platform to create human-relevant models of pancreatic ductal adenocarcinoma (PDAC). This initiative is particularly timely, given recent advancements in targeted therapies for pancreatic cancer, which highlight the necessity for improved patient stratification in treatment selection. Initial findings from this partnership are set to be showcased at the upcoming Pancreatic Cancer Action Network’s 2026 Scientific Summit in San Diego.
Inventia’s RASTRUM technology enables the precise printing of 3D pancreatic cancer models that can independently manipulate tumor and stromal components. Genialis enhances these models through its Supermodel, which utilizes a comprehensive transcriptomics dataset to correlate molecular states with clinical observations. This integration aims to address the challenge of identifying patients who could benefit most from new therapies.
As noted by the leadership of both companies, this collaboration represents a significant advancement in drug discovery, bridging the gap between clinical insights and experimental testing. By creating a feedback loop that connects patient data with laboratory models, Genialis and Inventia are poised to refine therapeutic hypotheses and improve patient outcomes in pancreatic cancer treatment. This innovative approach could reshape how new therapies are developed and validated, ultimately benefiting both patients and drug developers alike.